Clinical Trials Browser

Solid Tumor × tazemetostat × 90 days × Clear all

NCT05023655 2026-03-17

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Phase 2 Terminated

Other solid neoplasm

Solid Tumor